Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Interim CAR-T Data Support Kite’s BLA Submission Plans

Executive Summary

Kite Pharma Inc. executives reiterated plans on Sept. 26 to pursue US FDA approval this year for the chimeric antigen receptor T cell (CAR-T) therapy known as KTE-C19, keeping the company on track to seek accelerated approval for a form of advanced lymphoma before any of its competitors.

Advertisement

Related Content

ASH Ends With Consistent Kite CAR-T Data, Some Hope For Juno
Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place
Juno Stresses Differences Between Its CAR-Ts As JCAR015 Trial Put On Hold Again
Kite Pharma Details CAR-T Therapy Launch, Floats Pricing Benchmarks
Novartis Tests Global Manufacturing Process For CAR-T Therapy
INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve
CAR-T Update: Kite's Filing Coming Soon
Juno ROCKETs On Fast Clinical Hold Resolution
Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097370

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel